Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.
- Can Peptide Mapping Predict Intact Antibody PTM Distributions?
- The EU Overhauls Pharma Laws: What You Need To Know
- An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
- Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
- Is Your Supply Chain Ready For The End Of Class VI?
- When Lyophilization Fails At Scale, First Scrutinize Your Formulation
- The 5 Shifts That Could Remake Lyophilization By 2040
GUEST COLUMNISTS
-
Can Peptide Mapping Predict Intact Antibody PTM Distributions?
Peptide mapping quantifies modification at individual sites, but the same site-level results can correspond to different distributions across intact molecules.
-
The EU Overhauls Pharma Laws: What You Need To Know
On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
-
Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
Geopolitical shocks are reshaping outsourced pharmaceutical testing. Learn how procurement teams can strengthen resilience and protect continuity.
-
Is Your Supply Chain Ready For The End Of Class VI?
Revisions to USP <87> and <88> update biological reactivity testing — changes that are especially important for companies that rely on single-use technology.
-
When Lyophilization Fails At Scale, First Scrutinize Your Formulation
When lyophilizing a challenging biologic drug product, use an integrated approach optimizing formulation and process parameters together.
-
The 5 Shifts That Could Remake Lyophilization By 2040
Purdue University-based LyoHUB charts a risk-based course to modernizing freeze-drying technology for better performance and advanced modalities.
BIOSIMILAR WHITE PAPERS
-
Achieve Higher Targeted Concentrations
Single-pass TFF streamlines downstream processing by reducing footprint, shear exposure, and hold-up volumes. Learn how this approach is advancing efficiency across therapeutic and vaccine production.
-
Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer3/24/2025
Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency and innovation in bioprocessing workflows.
-
Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators4/28/2025
Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.
-
ADC Manufacturing: Practices, Challenges, And The Road Ahead6/15/2026
ADCs are advancing quickly, but manufacturing complexity is rising just as fast. Key challenges in scale-up, regulation, and costs are reshaping how the next generation of therapies will be delivered.
-
Reliability In Bioprocessing Is Your Competitive Advantage9/11/2026
Equipment reliability is a prerequisite for realizing value from digital transformation, automation, and data-driven initiatives in bioprocess manufacturing.
-
Solve ATMP Aseptic Filling Challenges With Gloveless Isolators1/9/2026
Human intervention is the top contamination risk in ATMP manufacturing. Robotic gloveless isolators address that risk through full automation and real-time monitoring during aseptic filling.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Teva And Samsung Bioepis Announce Agreement To Commercialize Two FDA-Approved Biosimilars In The U.S.
- Fresenius And WuXi Biologics Enter Exclusive Development Agreement To Expand Biosimilars Pipeline
- AAM Comments On Department Of Labor PBM Transparency And Disclosure Rule
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- Adalvo Expands Biosimilars Portfolio Through Acquisition Of Romiplostim Biosimilar Programme From Enzene
- FDA Approves Lucamzi – Biosimilar To Lucentis
- BioSim Proposes Incorporating Measures Into Electoral Programs To Promote Biosimilar Medicines
- Bio-Thera Announces NMPA Approval Of BAT2306, The First Secukinumab Biosimilar Approved In China
NEWSLETTER ARCHIVE
- 11.05.26 -- 7 Decisions To Make Before MES Configuration
- 10.29.26 -- How Indian Biosimilar Companies Are Poised To Succeed
- 10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You
- 10.22.26 -- Reduce risk. Move Annex 1 forward.
- 10.22.26 -- FDA Modernizes Container Closure Guidance: What Is Changing
